Oxaliplatin Eugia (Uk)

Oxaliplatin, the active ingredient in Oxaliplatin Eugia (Uk), is a platinum‑based chemotherapy agent presented as a sterile powder for intravenous infusion use. It is employed in combination regimens to treat colorectal cancer in adult patients. GNH USA supplies Oxaliplatin Eugia (Uk) as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

GNH USA supplies Oxaliplatin Eugia (Uk) as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Oxaliplatin is used primarily for colorectal cancer treatment, often as part of combination chemotherapy protocols.

- Metastatic colorectal cancer: enhances survival when combined with fluorouracil and leucovorin. - Adjuvant therapy for stage III colon or rectal cancer: reduces recurrence risk after surgical resection. - Advanced gastrointestinal tumours: used off‑label in clinical trials for gastric and pancreatic cancers.

Oxaliplatin may elicit a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Peripheral neuropathy: tingling or numbness, often worsening with cumulative dose. - Nausea and vomiting: may require anti‑emetic prophylaxis. - Diarrhoea: usually mild to moderate. - Fatigue: generalized tiredness during treatment cycles. - Thrombocytopenia: reduced platelet count observed in blood tests.

Serious or Rare Side Effects: - Severe peripheral neuropathy: persistent sensory loss that may be irreversible. - Acute allergic‑type reactions: flushing, shortness of breath, or hypotension during infusion. - Hematologic toxicity: neutropenia or severe anemia requiring medical intervention. - Hepatotoxicity: elevated liver enzymes indicating liver stress. - Cardiac arrhythmias: uncommon but reported during rapid infusions.

When handling Oxaliplatin, clinicians ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​  ​     ​  ​  ​  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...

-   t   t  d ... ... ... ... ... ... ............ ... ...  ... ... ... ... ... ... ... ... ... ... ... ......